A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BRC-201 in Adult and Adolescent Patients With Acute Uncomplicated Influenza Virus Infection
This is a Phase 3, multicenter, randomized, double-blind clinical study designed to evaluate the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza virus infection.
The study aims to assess the efficacy of BRC-201 in treating influenza symptoms and to evaluate its safety in patients with influenza.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Jaehyun Hwang
- 電話番号:+82 02-6072-2608
- メール:jhhwang@boryungbio.co.kr
研究場所
-
-
Seoul
-
Seoul、Seoul、韓国、08308
- 募集
- Korea University Guro Hospital
-
コンタクト:
- Misook Lee
- 電話番号:+82-2-2626-2462
- メール:rkafkatjr@korea.ac.kr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female participants aged 12 to less than 65 years who provide written informed consent or assent, as applicable.
- Laboratory-confirmed influenza A and/or B infection by RIDT or PCR, with an axillary temperature ≥38.0°C and at least one systemic and one respiratory symptom of moderate or greater severity (score ≥2).
- Onset of influenza-related symptoms within 48 hours before randomization.
- Willing and able to comply with the protocol-specified contraception requirements.
- Able to comply with study procedures, scheduled visits, and symptom diary completion.
Exclusion Criteria:
- Severe or critical influenza infection requiring hospitalization or intensive care.
- Significant uncontrolled underlying diseases or conditions associated with an increased risk of severe influenza, including immunodeficiency and clinically significant hepatic, renal, cardiovascular, or respiratory diseases.
- Suspected or confirmed lower respiratory tract disease on chest X-ray, recent acute respiratory infection, or concomitant infection requiring systemic antimicrobial treatment.
- Clinically significant infection-related findings, including leukocyte count >10.0 × 10⁹/L, purulent sputum, or purulent tonsillitis.
- History of dysphagia, gastrointestinal conditions affecting drug absorption, or hypersensitivity to the investigational product, acetaminophen, or NSAIDs.
- BMI >30.0 kg/m², body weight <40.0 kg, or positive COVID-19 test at screening.
- Use of anti-influenza medication within 7 days, or another investigational drug or device treatment within 30 days before randomization.
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:BRC-201
Participants will receive a single oral dose of BRC-201 (40 mg for participants weighing less than 80 kg or 80 mg for those weighing 80 kg or more). |
BRC-201 (pixavir marboxil) 20 mg capsules administered orally as a single dose of 40 mg (2 capsules) for participants weighing less than 80 kg or 80 mg (4 capsules) for participants weighing 80 kg or more.
他の名前:
|
|
プラセボコンパレーター:Placebo
Participants will receive a single oral dose of placebo matching BRC-201 (2 capsules for participants weighing less than 80 kg or 4 capsules for those weighing 80 kg or more). |
Placebo capsules matching BRC-201, administered orally as a single dose of 2 capsules for participants weighing less than 80 kg or 4 capsules for participants weighing 80 kg or more. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to Alleviation of Influenza-related Symptoms (TTAS)
時間枠:From Day 1 (post-dose) through Day 14
|
Time (hours) from the initiation of investigational medicinal product administration until all seven influenza-related symptoms (cough, sore throat, nasal congestion, headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain) are alleviated. Symptom alleviation is defined as a severity score of 0 (none) or 1 (mild) for all seven symptoms, maintained for at least 21.5 hours. |
From Day 1 (post-dose) through Day 14
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Alleviation of Influenza-related Symptoms at Each Time Point
時間枠:From Day 1 (post-dose) through Day 14
|
The percentage of participants whose severity scores for all seven influenza-related symptoms (cough, sore throat, nasal congestion, headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain) are 0 (none) or 1 (mild), with symptom alleviation maintained for at least 21.5 hours, at each assessment time point. |
From Day 1 (post-dose) through Day 14
|
|
Change From Baseline in Composite Influenza Symptom Score at Each Time Point
時間枠:Baseline (Day 1, pre-dose) through Day 14
|
Change from baseline in the composite score of seven influenza-related symptoms (cough, sore throat, nasal congestion, headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain). Each symptom is assessed using a 4-point severity scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). The composite score ranges from 0 to 21, with higher scores indicating greater symptom severity. The change is calculated as the score at each post-baseline assessment minus the baseline score. |
Baseline (Day 1, pre-dose) through Day 14
|
|
Time to Alleviation of Four Systemic Influenza Symptoms
時間枠:From Day 1 (post-dose) through Day 14
|
Time (hours) from the initiation of investigational medicinal product administration until all four systemic influenza symptoms (headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain) are alleviated. Symptom alleviation is defined as a severity score of 0 (none) or 1 (mild) for all four systemic symptoms. |
From Day 1 (post-dose) through Day 14
|
|
Time to Alleviation of Three Respiratory Influenza Symptoms
時間枠:From Day 1 (post-dose) through Day 14
|
Time (hours) from the initiation of investigational medicinal product administration until all three respiratory influenza symptoms (cough, sore throat, and nasal congestion) are alleviated. Symptom alleviation is defined as a severity score of 0 (none) or 1 (mild) for all three respiratory symptoms. |
From Day 1 (post-dose) through Day 14
|
|
Time to Alleviation of Each Individual Influenza-related Symptom
時間枠:From Day 1 (post-dose) through Day 14
|
Time (hours) from the initiation of investigational medicinal product administration until alleviation of each of the seven influenza-related symptoms (cough, sore throat, nasal congestion, headache, feeling feverish or chills/sweats, fatigue, and muscle or joint pain). Alleviation of an individual symptom is defined as a severity score of 0 (none) or 1 (mild), maintained for at least 21.5 hours. Each symptom will be evaluated separately. Participants with a baseline severity score of 0 or 1 for a specific symptom will be excluded from the analysis of that symptom. |
From Day 1 (post-dose) through Day 14
|
|
Percentage of Participants With Normalized Body Temperature at Each Time Point
時間枠:From Day 1 (post-dose) through Day 14
|
The percentage of participants whose body temperature returned to normal at each assessment time point after investigational medicinal product administration. Normalization of body temperature is defined as an axillary temperature below 37.0°C. |
From Day 1 (post-dose) through Day 14
|
|
Time to Resolution of Fever
時間枠:From Day 1 (post-dose) through Day 14
|
Time (hours) from the initiation of investigational medicinal product administration until resolution of fever. Fever resolution is defined as body temperature below 37.0°C, maintained for at least 12 hours. |
From Day 1 (post-dose) through Day 14
|
|
Body Temperature at Each Time Point
時間枠:From Day 1 (post-dose) through Day 14
|
Axillary body temperature (°C) measured by participants using an electronic thermometer at each assessment time point after investigational medicinal product administration. Body temperature will be summarized by treatment group at each time point. |
From Day 1 (post-dose) through Day 14
|
|
Time to Recovery to Pre-influenza Health Status
時間枠:From Day 1 (post-dose) through Day 14
|
Time (hours) from the initiation of investigational medicinal product administration until recovery to pre-influenza health status. Recovery is defined as a participant-reported health status score greater than or equal to the pre-influenza health status score recorded before dosing on Day 1. Health status is assessed using an 11-point scale ranging from 0 (worst health status) to 10 (normal health status considering the participant's age and condition). |
From Day 1 (post-dose) through Day 14
|
|
Change From Baseline in EuroQol Visual Analog Scale (EQ VAS) Score at Each Time Point
時間枠:Baseline (Day 1, pre-dose) through Day 14
|
Change from baseline in the EuroQol Visual Analog Scale (EQ VAS) score at each post-baseline assessment time point. Participants rate their overall health status on a scale ranging from 0 (the worst health they can imagine) to 100 (the best health they can imagine). Higher scores indicate better self-reported health status. Change from baseline is calculated as the post-baseline EQ VAS score minus the baseline score. |
Baseline (Day 1, pre-dose) through Day 14
|
|
Incidence of Influenza-related Complications
時間枠:From Day 1 (post-dose) through Day 15 (±2 days)
|
The percentage of participants experiencing influenza-related complications, including hospitalization, death, sinusitis, bronchitis, otitis media, and radiographically confirmed pneumonia. Complications are assessed by the investigator at each scheduled study visit. The number and percentage of participants experiencing complications and the number of occurrences will be summarized by treatment group. |
From Day 1 (post-dose) through Day 15 (±2 days)
|
|
Percentage of Participants Receiving Rescue Medication and Frequency of Administration
時間枠:From Day 1 (post-dose) through Day 14
|
The percentage of participants who receive rescue medication (acetaminophen) at least once after investigational medicinal product administration and the number of rescue medication administrations. Rescue medication use, including the date, time, and dose of each administration, is recorded in the participant diary and summarized by treatment group. |
From Day 1 (post-dose) through Day 14
|
|
Percentage of Participants With Positive Influenza Virus Titer by Viral Culture at Each Time Point
時間枠:From Day 2 through Day 15 (±2 days)
|
The percentage of participants with a positive influenza virus titer by viral culture at each post-dose assessment time point. Positive results are defined as detectable viral titers or values at or above the lower limit of quantification (LLOQ). The percentage will be summarized by treatment group. The analysis includes participants with positive viral RNA results or values at or above the LLOQ by RT-PCR at screening. |
From Day 2 through Day 15 (±2 days)
|
|
Percentage of Participants With Positive Influenza Viral RNA by RT-PCR at Each Time Point
時間枠:From Day 2 through Day 15 (±2 days)
|
The percentage of participants with positive influenza viral RNA results by reverse transcription polymerase chain reaction (RT-PCR) at each post-dose assessment time point. Positive results are defined as detectable viral RNA or viral RNA levels at or above the lower limit of quantification (LLOQ). Results will be summarized by treatment group. The analysis includes only participants with positive viral RNA results or values at or above the LLOQ by RT-PCR at screening. |
From Day 2 through Day 15 (±2 days)
|
|
Change From Baseline in Influenza Virus Titer at Each Time Point
時間枠:Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)
|
Change from baseline in influenza virus titer measured by viral culture at each post-dose assessment time point. Viral titers are expressed as log10 TCID50/mL (50% tissue culture infectious dose per milliliter). Change from baseline is calculated as the post-baseline viral titer minus the baseline viral titer. Negative changes indicate a reduction in infectious viral titer. |
Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)
|
|
Change From Baseline in Influenza Viral RNA Load at Each Time Point
時間枠:Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)
|
Change from baseline in influenza viral RNA load measured by reverse transcription polymerase chain reaction (RT-PCR) at each post-dose assessment time point. Viral RNA load is expressed as log10 viral copies/mL. Change from baseline is calculated as the post-baseline viral RNA load minus the baseline viral RNA load. Negative changes indicate a reduction in viral RNA load. |
Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)
|
|
Time to Cessation of Influenza Virus Detection
時間枠:From Day 1 (post-dose) through Day 15 (±2 days)
|
Time (hours) from the initiation of investigational medicinal product administration to the first assessment at which influenza viral RNA is negative or below the lower limit of quantification (LLOQ), as determined by reverse transcription polymerase chain reaction (RT-PCR) testing of nasopharyngeal swab specimens. |
From Day 1 (post-dose) through Day 15 (±2 days)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PA Gene Polymorphisms and Treatment-emergent Amino Acid Substitutions
時間枠:Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)
|
Assessment of polymerase acidic (PA) gene polymorphisms and treatment-emergent amino acid substitutions in evaluable influenza viruses using PA gene sequencing of nasopharyngeal swab specimens. |
Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)
|
|
Drug Susceptibility of Evaluable Influenza Viruses
時間枠:Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)
|
Assessment of antiviral drug susceptibility in evaluable influenza viruses isolated from nasopharyngeal swab specimens collected during the study. Drug susceptibility testing will be performed to evaluate changes in antiviral susceptibility in evaluable viruses. |
Baseline (Screening or Day 1, pre-dose) through Day 15 (±2 days)
|
|
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
時間枠:From Day 1 (post-dose) through Day 15 (±2 days)
|
The percentage of participants experiencing at least one treatment-emergent adverse event (TEAE). A TEAE is defined as an adverse event that occurs after administration of the investigational medicinal product or a pre-existing condition that worsens after administration. TEAEs will be summarized by treatment group according to severity, seriousness, causality, and MedDRA System Organ Class and Preferred Term. |
From Day 1 (post-dose) through Day 15 (±2 days)
|
|
Percentage of Participants With Serious Adverse Events (SAEs)
時間枠:From informed consent through Day 15 (±2 days)
|
The percentage of participants experiencing at least one serious adverse event (SAE) during the clinical trial. Serious adverse events will be collected regardless of their causal relationship to the investigational medicinal product. The number and percentage of participants with SAEs and the number of events will be summarized by treatment group. |
From informed consent through Day 15 (±2 days)
|
|
Percentage of Participants With Clinically Significant Laboratory Abnormalities
時間枠:Baseline (pre-dose) through Day 15 (±2 days)
|
The percentage of participants with at least one clinically significant abnormality in clinical laboratory tests, including hematology, blood chemistry, coagulation, and urinalysis. Clinically significant abnormalities are defined as changes from normal or abnormal not clinically significant (NCS) at baseline to abnormal clinically significant (CS) after administration of the investigational medicinal product, as assessed by the investigator. |
Baseline (pre-dose) through Day 15 (±2 days)
|
|
Change From Baseline in Systolic Blood Pressure
時間枠:Baseline (pre-dose) through Day 15 (±2 days)
|
Change from baseline in systolic blood pressure (mmHg) at scheduled post-dose study visits. Baseline is defined as the most recent measurement before administration of the investigational medicinal product. Change from baseline is calculated as the post-baseline value minus the baseline value. |
Baseline (pre-dose) through Day 15 (±2 days)
|
|
Change From Baseline in Diastolic Blood Pressure
時間枠:Baseline (pre-dose) through Day 15 (±2 days)
|
Change from baseline in diastolic blood pressure (mmHg) at scheduled post-dose study visits. Baseline is defined as the most recent measurement before administration of the investigational medicinal product. Change from baseline is calculated as the post-baseline value minus the baseline value. |
Baseline (pre-dose) through Day 15 (±2 days)
|
|
Change From Baseline in Pulse Rate
時間枠:Baseline (pre-dose) through Day 15 (±2 days)
|
Change from baseline in pulse rate (beats/min) at scheduled post-dose study visits. Baseline is defined as the most recent measurement before administration of the investigational medicinal product. Change from baseline is calculated as the post-baseline value minus the baseline value. |
Baseline (pre-dose) through Day 15 (±2 days)
|
|
Change From Baseline in Respiratory Rate
時間枠:Baseline (pre-dose) through Day 15 (±2 days)
|
Change from baseline in respiratory rate (breaths/min) at scheduled post-dose study visits. Baseline is defined as the most recent measurement before administration of the investigational medicinal product. Change from baseline is calculated as the post-baseline value minus the baseline value. |
Baseline (pre-dose) through Day 15 (±2 days)
|
|
Percentage of Participants With Clinically Significant 12-Lead ECG Abnormalities
時間枠:Baseline (pre-dose) through Day 15 (±2 days)
|
The percentage of participants with at least one clinically significant abnormality in 12-lead electrocardiogram (ECG) findings after administration of the investigational medicinal product. Clinically significant abnormalities are defined as changes from normal or abnormal not clinically significant (NCS) at baseline to abnormal clinically significant (CS) after administration, as assessed by the investigator. |
Baseline (pre-dose) through Day 15 (±2 days)
|
|
Percentage of Participants With Clinically Significant Physical Examination Abnormalities
時間枠:Baseline (pre-dose) through Day 15 (±2 days)
|
The percentage of participants with at least one clinically significant abnormality in physical examination findings after administration of the investigational medicinal product. Clinically significant abnormalities are defined as changes from normal or abnormal not clinically significant (NCS) at baseline to abnormal clinically significant (CS) after administration, as assessed by the investigator. Physical examinations include assessments of the mucocutaneous system, lymph nodes, head and neck, chest, abdomen, spine and extremities, and nervous system. |
Baseline (pre-dose) through Day 15 (±2 days)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- BR-FLU-CT-301
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual participant data (IPD) underlying the results reported in publications may be made available to qualified researchers upon reasonable request. Requests will be reviewed by Boryung Biopharma Co., Ltd., considering the scientific merit of the proposed research, participant confidentiality, and applicable regulatory requirements. Approved requests will be subject to a data-sharing agreement.
IPD 共有アクセス基準
Qualified researchers may request access to de-identified IPD for scientifically valid research purposes. Requests will be reviewed by the Sponsor on a case-by-case basis. Data access will be granted following approval of the request and execution of an appropriate data-sharing agreement, subject to applicable privacy and regulatory requirements.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。